[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100124362":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":26,"centralContacts":11,"locations":30,"responsibleParty":44,"collaborators":11,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":11,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence 1","EXPERIMENTAL",null,[13],"Drug: PF-04447943",{"label":15,"type":10,"description":11,"interventionNames":16},"Sequence 2",[13],[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","PF-04447943","35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2",[9],{"type":19,"name":20,"description":24,"armGroupLabels":25,"otherNames":11},"35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.",[15],[27],{"name":28,"affiliation":5,"role":29},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[31],{"facility":32,"status":11,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":11},"Pfizer Investigational Site","New Haven","Connecticut","06511","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-72.92816,41.30815,{"lat":42,"lon":41},{"type":11,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":45,"oldOrganization":46},"Director, Clinical Trial Disclosure Group","Pfizer, Inc.","100124362","phase-1-a-study-to-evaluate-whether-food-affects-the-plasma-drug-levels-of-a-35-mg-single-dose-of-pf-04447943-taken-orally-in-healthy-adult-participants-100124362",false,"NCT00886093","A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants","A Phase 1, Open Label, Randomized, Single Dose, Cross-Over Study To Evaluate The Effect Of Food On PF-04447943 Pharmacokinetics In Healthy Adult Subjects","Inclusion Criteria:\n\n* Healthy male and\u002For female subjects, not of child bearing potential.\n* Age 18-55 inclusive\n* Total body weight \\>50 kg.\n\nExclusion Criteria:\n\n* Evidence or history of clinical significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic diseases\n* History of orthostatic blood pressure changes or orthostatic symptoms\n* Greater than 7 drinks of alcohol per week for women and greater than 14 drinks per week for men\n* Smoking more than 5 cigarettes per day",true,"ALL","18 Years","55 Years",{"count":59,"type":60},10,"ACTUAL","INTERVENTIONAL",[63],"PHASE1","The purpose of the study is to compare the plasma drug levels of PF-04447943 when taken as a 35 mg tablet after a high fat meal compared to when taken after fasting. Healthy adult volunteers will receive a single dose of the drug once when fasted and again when fed. The safety and tolerability of the drug will be monitored.",[66],"Healthy",[68],"pharmacokinetics, single dose, crossover, fed vs fasted state","COMPLETED","2009-06-29",{"date":72,"type":73},"2009-07-02","ESTIMATED",{"date":75,"type":11},"2009-04",{"date":77,"type":60},"2009-05",{"name":5,"class":6},1]